ARTHEx Biotech has successfully closed a $87 million Series B financing round led by Bpifrance to advance its clinical development of ATX-01 for Myotonic Dystrophy Type 1 and expand its RNA medicine pipeline.

Information on the Target

ARTHEx Biotech S.L. is a clinical-stage biotechnology company based in Valencia, Spain, specializing in the development of targeted RNA medicines aimed at rare genetic neuromuscular disorders. The company has recently completed a $87 million upsized Series B financing round, which was led by new investor Bpifrance along with contributions from all existing investors, including AdBio Partners, CDTI Innovación, Columbus Venture Partners, the European Innovation Council (EIC), Hadean Ventures, Invivo Partners, and Sound Bioventures.

The primary focus of the funding will support the clinical advancement of ARTHEx's lead program, ATX-01, designed for Myotonic Dystrophy Type 1 (DM1). Currently in Phase I-IIa, this unique therapy targets microRNA23b (miR-23b) to assist in ameliorating the symptoms associated with DM1.

Industry Overview in Spain

The biotechnology sector in Spain has seen substantial growth over the past decade, driven by significant investment and innovation in drug development, particularly fo